Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients

Sep 26, 2019 14:08 JST

Source: Eisai

TOKYO, Sep 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. The Coroban predicts inpatients' tumbling and falling risks in advance and displays alerts.

Through the launch of antiosteoporotic agent and insomnia treatment, a pharmaceutical company Eisai has recognized that the preventive measures for tumbling and falling at medical institutions are important. On the other hand, FRONTEO Healthcare, Inc., a wholly owned subsidiary of FRONTEO, is a data analysis corporation focused on healthcare. It has originally developed an artificial intelligence (AI) system called Concept Encoder based on natural language processing technique.

Eisai and FRONTEO have started the joint development for the Coroban since January 2018. The Coroban was introduced to several medical institutions in Japan on a trial basis by leveraging Eisai's network with medical institutions, and advancing the improvements of Coroban based on needs in the clinical settings has led to the launch of the Coroban this time.

According to a survey by the Ministry of Health, Labour and Welfare, the number of inpatients aged 65 and over tends to increase to about 960,000 in 2017, therefore, the importance of cares for tumbling and falling in medical institutions is increasing. The Coroban learns the nursing records of past inpatients at each medical institution, scores the tumbling and falling risks of individual inpatient from the daily nursing records based on these past records, and displays the information of inpatients with high risks. It is expected to reduce the burden of medical professionals and to make the risk assessment uniform and objective by reflecting the information in individual care and nursing plans for each patient's tumbling and falling with the Coroban.

Through the launch of the Coroban which supports to establish systems at nursing ward to reduce the tumbling and falling risks of inpatients, Eisai and Fronteo aim to contribute to the realization of well-being of patients and their families.

About the tumbling and falling prediction system Coroban

Product name: Tumbling and Falling Prediction System Coroban
* The Coroban is not a medical device.

About Concept Encoder AI system

Concept Encoder is the AI system developed by FRONTEO Healthcare. Inc. specifically for the healthcare industry. The system was developed with the aim of effective, evidence-based analysis and utilization of healthcare-related big data, including large bodies of free-entry text data. The program incorporates significance tests and other crucial statistical methods for evidence-based medicine (EBM), the gold standard of practice among healthcare professionals, and applies this to natural language analysis. For more information, visit https://www.fronteo- healthcare.com/conceptencoder.

About FRONTEO, Inc. and FRONTEO Healthcare, Inc.

FRONTEO, Inc. supports the analysis of big data based on behavior informatics by utilizing its originally developed AI technology, "KIBIT". FRONTEO was found in 2003, and has ever since been developing our business primarily in the field of LegalTech including "eDiscovery" (preserve, process review, and analyze electronically stored data that could be evidence doe litigation process) and "digital forensics", as well as initiatives "Securely Identify Risks and Opportunities Buried in Records" in the field of business intelligence. FRONTEO Healthcare, Inc. was found in 2015. Through its data analysis capability, FRONTEO Healthcare, Inc. hopes to support people around the world in receiving the best healthcare services and pave the way to a healthier, more secure future.

For more information about FRONTEO, Inc. and FRONTEO Healthcare, Inc., please visit http://www.fronteo.com/ http://www.fronteo-healthcare.com/

Contact:

Media Inquiries:
Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China

February 10 2026 12:34 JST

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

February 06 2026 10:31 JST

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

January 26 2026 10:37 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time

January 21 2026 15:44 JST

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

January 13 2026 08:50 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

January 06 2026 09:43 JST

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

December 03 2025 17:19 JST

More Press release >>

Latest Press Release

Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST

Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST

Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST

Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST

Honda Works Partner Aston Martin Aramco Formula One(TM) Team Unveils Livery of "AMR26" F1(TM) Machine Equipped with Honda Power Unit Ahead of the 2026 Race Season
Feb 10, 2026 18:25 JST

Honda to Make Organizational Changes to Further Enhance Competitiveness its Motorcycle, Automobile and Power Products Business
Feb 10, 2026 17:53 JST

KS Energy and Hitachi Collaborate on Extra-High Voltage Battery Energy Storage System
Feb 10, 2026 14:15 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 10, 2026 13:34 JST

NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
Feb 09, 2026 21:18 JST

CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 09, 2026 14:28 JST

JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 09, 2026 14:00 JST

Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 09, 2026 11:00 JST

Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market
Feb 06, 2026 13:34 JST

Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products
Feb 06, 2026 11:50 JST

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Feb 06, 2026 11:31 JST

Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization
Feb 06, 2026 11:14 JST

Genesys and Fujitsu Transform AEON Financial Service's Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times
Feb 06, 2026 10:44 JST

TANAKA PRECIOUS METAL TECHNOLOGIES establishes total solutions system for contract manufacturing of various test kits including in vitro diagnostics
Feb 05, 2026 22:00 JST

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 05, 2026 11:55 JST

Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 05, 2026 11:48 JST

More Latest Release >>